MBX Biosciences doses first patient in Phase 3 hypoparathyroidism trial

August 27, 2026 8:01 AM

MBX Biosciences, Inc. (Nasdaq: MBX) announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found